Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
Launched by SUN YAT-SEN UNIVERSITY · May 30, 2024
Trial Information
Current as of February 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new test designed to help diagnose nasopharyngeal carcinoma, a type of cancer that affects the area behind the nose. The researchers want to see how well this test, which checks for specific changes in the Epstein-Barr virus (EBV) DNA, works in identifying this cancer. Participants will undergo various tests, including blood tests for EBV antibodies and a biopsy to confirm the diagnosis.
To join the study, participants should have symptoms that might suggest nasopharyngeal carcinoma and test positive for EBV-related markers. However, individuals who have already been treated for this cancer or have had a relapse cannot participate. If eligible, participants can expect a thorough evaluation involving swabs and tests, contributing to the understanding of this new diagnostic tool and potentially improving future cancer diagnosis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Participants who meet the following Article 1 and also meet one of Articles 2 to 6 can be enrolled:
- • Understand, sign, and date the informed consent document to participate in the study
- • Display one or more symptoms or signs indicative of nasopharyngeal carcinoma
- • Test positive for EBV antibodies or EBV DNA
- • Be diagnosed with other head and neck carcinomas
- • Be diagnosed with malignancies associated with EBV infection
- • Require differential diagnosis from nasopharyngeal carcinoma during endoscopic or other imaging examinations
- • Fulfill any additional conditions deemed appropriate by the investigator for inclusion in this study
- Exclusion Criteria:
- • Have been diagnosed with nasopharyngeal carcinoma and have undergone treatment
- • Experience relapse or metastasis of nasopharyngeal carcinoma following treatment
- • Have unsuccessful nasopharyngeal swab collections
- • Present any other conditions considered by the investigator as unsuitable for participation in this trial
Trial Officials
Hai-Qiang Mai
Study Chair
Sun Yat-sen University
Zhen-Zhou Xiao
Principal Investigator
Fujian Cancer Hospital
Min-Zhong Tang
Principal Investigator
Wuzhou Red Cross Hospital
Min-Yi Fu
Principal Investigator
Zhongshan People's Hospital, Guangdong, China
Zhe Zhang
Principal Investigator
First Affiliated Hospital of Guangxi Medical University
About Sun Yat Sen University
Sun Yat-sen University, a prestigious institution located in Guangzhou, China, is dedicated to advancing medical research and healthcare innovations. As a leading clinical trial sponsor, the university leverages its extensive academic resources and collaboration with top-tier medical professionals to conduct rigorous clinical studies. Committed to improving patient outcomes and contributing to global health knowledge, Sun Yat-sen University focuses on a wide range of therapeutic areas, employing cutting-edge methodologies to ensure the integrity and efficacy of its research initiatives. Through its clinical trials, the university aims to foster scientific advancements and enhance the quality of care provided to patients both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Nanning, Guangxi, China
Fuzhou, Fujian, China
Zhongshan, Guangdong, China
Wuzhou, Guangxi, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0